Redeye raises the fair value of Optomed to EUR 13 per share, a new bull case of EUR 17 per share and a bear case of EUR 5. As we expected, the trend for "remote-everything" favours Optomed. We believe this transformation will continue and even accelerate in the coming years and see Optomed as positioned for strong growth with both superior technology and solid execution capability.